Molecular therapy for Human Leukemias: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 31/December/2016, 12.16 pm

Natural product-derived regenerative therapy for improving muscle repair and strength in the elderly: γ-Bisabolene, found in Cardamom, cubeb, lemon and oregano, decreases the expression of HOXA9, increases skeletal muscle regeneration and improves muscle stem cells function and repair via up regulation of its target genes, 31/December/2016, 11.56 pm
December 31, 2016
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Panax notoginseng saponins, isolated from Panax notoginseng (Burk), increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 1/January/2017, 11.23 am
January 1, 2017
Show all

Introduction: What they say

Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” 


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Human Leukemias: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4


From Research findings to Therapeutic opportunity:

This study suggests that LRRC4/NGL-2, by increasing the expression of  its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).

price-100

[easy_payment currency=”USD”]

Taken together, this study suggests that pharmacological formulations encompassing       LRRC4/NGL-2 activator(s) either alone or  in combination with other anticancer drugs may be used to inhibit B-Cell and myeloid leukemias.

lrrc4-ngl2-induces-irf4-expression

Figure 1 Mechanistic insight into how LRRCD/NGL-2 increases the expression of IRF4 to prevent cancer progression


Details of the research details

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How LRRC4/NGL-2 increases the expression of IRF4?

Amount: $ 100

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or newbioideas.com

CitationBoominathan, L., Molecular therapy for Human Leukemias: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 31/December/2016, 12.16 pm,  Genome-2-Bio-Medicine Discovery Center.

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.